Latest News about Phase 3 Trial
Recent news which mentions Phase 3 Trial
BELLUS Health Announces FDA End-of-Phase 2 Meeting For Refractory Chronic Cough Program
July 12, 2022
Tickers
BLU
From Benzinga
Pfizer's Ulcerative Colitis Candidate Shows Remission In Over 30% Of Patients In Pivotal Studies
May 24, 2022
Tickers
PFE
From Benzinga
From Benzinga
Bristol Myers' Neoadjuvant Opdivo/Chemo Improves Event-Free Survival In Early-Stage Lung Cancer Patients
April 11, 2022
Tickers
BMY
From Benzinga
Veru's Stock Nearly Triples As COVID-19 Drugs Cuts Reduces Deaths By 55% In Hospitalized Patients
April 11, 2022
Tickers
VERU
From Benzinga
Vaxxinity Receives $9.25M Funding From CEPI To Support Pivotal COVID-19 Vaccine Trial
April 07, 2022
Tickers
VAXX
From Benzinga
Biophytis Shares Fall As It Stops Enrollment In Sarconeos COVID-19 Trial, Data Expected In Q3 2022
April 07, 2022
Tickers
BPTS
From Benzinga
AstraZeneca's Ultomiris Shows Sustained Improvements In Functional Activities In Neuromuscular Disease
April 06, 2022
From Benzinga
Novartis Highlights Four-Year Efficacy, Safety Data On Kesimpta In Multiple Sclerosis
April 05, 2022
Tickers
NVS
From Benzinga
Theravance Biopharma's Ampreloxetine Shows Benefit In Atrophy Patients, But Not In Parkinson's
April 05, 2022
Tickers
TBPH
From Benzinga
Lexicon Touts New Favorable Data On Sotaglifozin Cardio Data
April 04, 2022
Tickers
LXRX
From Benzinga
Merck - Ridgeback's COVID-19 Antiviral Shows Rapid Elimination Of Infectious SARS-CoV-2 Than Placebo
April 01, 2022
Tickers
MRK
From Benzinga
Sorrento To Start Late-Stage Trial Of Abivertinib In Critically-Ill COVID-19 Patients
March 31, 2022
Tickers
SRNE
From Benzinga
InflaRx Shares Plunge After Disappointing Results On Vilobelimab In Critically Ill COVID-19 Patients
March 31, 2022
Tickers
IFRX
From Benzinga
From Benzinga
Incyte-Lilly's Olumiant Continue To Show Improved Scalp, Eyebrows, Eyelash Hair Regrowth At 52 Weeks
March 28, 2022
From Benzinga
Roivant' Dermavant Showcases New Long-Term Durability, Tolerability Data For Plaque Psoriasis Candidate
March 25, 2022
Tickers
ROIV
From Benzinga
From Benzinga
Pfizer's Ulcerative Colitis Candidate Aces Late-Stage Study
March 23, 2022
Tickers
PFE
From Benzinga
ObsEva Unveils Additional Efficacy Results for Linzagolix In Endometriosis-Associated Pain
March 22, 2022
Tickers
OBSV
From Benzinga
Tonix Says Fibromyalgia Candidate Failed To Achieve Statistical Significance Over Placebo
March 21, 2022
Tickers
TNXP
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
|
|
|